Back

PCSK9 inhibition and clinical cardiovascular outcomes in patients with atherosclerotic cardiovascular disease

Cardiovascular Research

22 June 2017
Organised by: Logo
Read full article
ESC Journals

Contributors

Ulf Landmesser
Ulf Landmesser

Author

Charite University Hospital Berlin , Germany

You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials
27 August 2022
thumbnail
Congress Presentation
Carotid plaques stabilization and regression with evolocumab
1 September 2025
thumbnail
Congress Presentation
Lower rate of ischemic events with PCSK9 inhibition in patients with atherosclerotic cardiovascular disease but without prior ischemic events
30 August 2024
thumbnail
Webinar
Update of the 2019 ESC Guidelines on Management of Dyslipidaemia: new recommendations and their impact on clinical practice
25 November 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources